STOCK TITAN

Karyopharm to Participate at the Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced its senior management will engage in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 a.m. ET in Miami, Florida. This event highlights Karyopharm's pioneering role in developing cancer therapies, particularly with its lead product, XPOVIO® (selinexor), which is approved for multiple oncology indications.

Investors can access a live webcast of this chat and related slides via the company's investor site, with a replay available for 90 days post-event.

Positive
  • None.
Negative
  • None.

NEWTON, Mass., March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference. The conference is being held in Miami, Florida and the fireside chat will take place on Wednesday, March 16, 2022 at 10:15 a.m. ET.

A live webcast of the fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event. 

About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

SOURCE Karyopharm Therapeutics Inc.

Cision View original content:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-barclays-global-healthcare-conference-301498394.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm's fireside chat at the Barclays Global Healthcare Conference?

Karyopharm's fireside chat is scheduled for March 16, 2022, at 10:15 a.m. ET.

Where is the Barclays Global Healthcare Conference being held?

The Barclays Global Healthcare Conference is being held in Miami, Florida.

How can I access the webcast of Karyopharm's fireside chat?

The webcast and accompanying slides can be accessed under the 'Events & Presentations' section on Karyopharm's investor website.

What is Karyopharm's lead product?

Karyopharm's lead product is XPOVIO® (selinexor), approved for various oncology indications.

How long will the replay of the fireside chat be available?

The replay of the fireside chat will be available for 90 days after the event.

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

KPTI Rankings

KPTI Latest News

KPTI Stock Data

79.84M
118.24M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON